Grail was founded by gene sequencing company Illumina Inc in 2016, with investments from ARCH Venture Partners, Sutter Hill Ventures and Bezos Expeditions, the venture investment fund of Jeff Bezos.
The company, which is developing a blood test to identify early-stage cancers, has set a placeholder amount of $100 million for the IPO, without disclosing the size of its offering.
Illumina is the majority shareholder in Grail with a 14.6% stake, according to the company's filing with U.S. securities regulators.
Morgan Stanley, Goldman Sachs & Co LLC, and BofA Securities are acting as lead bookrunners for the proposed offering. The company has applied to list its stock on the Nasdaq under the ticker symbol "GRAL".
(Reporting by Manas Mishra and Abhishek Manikandan in Bengaluru; Editing by Shounak Dasgupta and Shailesh Kuber)